Statins in liver disease: not only prevention of cardiovascular events

Expert Rev Gastroenterol Hepatol. 2018 Aug;12(8):743-744. doi: 10.1080/17474124.2018.1477588. Epub 2018 May 24.
No abstract available

Keywords: Fatty liver; cardiovascular risk; drug safety; fatty liver; hydroxymethylglutaryl-CoA reductase inhibitors; non-alcoholic fatty liver disease.

Publication types

  • Editorial
  • Review

MeSH terms

  • Cardiovascular Diseases / etiology
  • Cardiovascular Diseases / prevention & control*
  • Disease Progression
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Hypolipidemic Agents / therapeutic use*
  • Non-alcoholic Fatty Liver Disease / complications
  • Non-alcoholic Fatty Liver Disease / drug therapy*

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Hypolipidemic Agents